These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23901771)

  • 1. In ovo vaccination of commercial broilers with a glycoprotein J gene-deleted strain of infectious laryngotracheitis virus.
    Mashchenko A; Riblet SM; Zavala G; García M
    Avian Dis; 2013 Jun; 57(2 Suppl):523-31. PubMed ID: 23901771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and vaccine efficacy of a glycoprotein G deficient strain of infectious laryngotracheitis virus delivered in ovo.
    Legione AR; Coppo MJ; Lee SW; Noormohammadi AH; Hartley CA; Browning GF; Gilkerson JR; O'Rourke D; Devlin JM
    Vaccine; 2012 Nov; 30(50):7193-8. PubMed ID: 23084851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vivo safety and efficacy of a glycoprotein G-deficient candidate vaccine strain of infectious laryngotracheitis virus delivered via eye drop.
    Coppo MJ; Noormohammadi AH; Hartley CA; Gilkerson JR; Browning GF; Devlin JM
    Avian Pathol; 2011 Aug; 40(4):411-7. PubMed ID: 21812721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation and Protection Efficacy of a Recombinant Infectious Laryngotracheitis Virus (ILTV) Depleted of Open Reading Frame C (ΔORFC) when Delivered in ovo.
    Schneiders GH; Riblet SM; García M
    Avian Dis; 2018 Jun; 62(2):143-151. PubMed ID: 29944395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of live virus vaccines against infectious laryngotracheitis assessed by polymerase chain reaction-restriction fragment length polymorphism.
    Han MG; Kim SJ
    Avian Dis; 2003; 47(2):261-71. PubMed ID: 12887186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single Nucleotide Polymorphism Genotyping Analysis Shows That Vaccination Can Limit the Number and Diversity of Recombinant Progeny of Infectious Laryngotracheitis Viruses from the United States.
    Loncoman CA; Hartley CA; Coppo MJC; Browning GF; Beltrán G; Riblet S; Freitas CO; García M; Devlin JM
    Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30242009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection induced by commercially available live-attenuated and recombinant viral vector vaccines against infectious laryngotracheitis virus in broiler chickens.
    Vagnozzi A; Zavala G; Riblet SM; Mundt A; García M
    Avian Pathol; 2012; 41(1):21-31. PubMed ID: 22845318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against infectious laryngotracheitis by in ovo vaccination with commercially available viral vector recombinant vaccines.
    Johnson DI; Vagnozzi A; Dorea F; Riblet SM; Mundt A; Zavala G; García M
    Avian Dis; 2010 Dec; 54(4):1251-9. PubMed ID: 21313847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges.
    Zhao W; Spatz S; Zhang Z; Wen G; Garcia M; Zsak L; Yu Q
    J Virol; 2014 Aug; 88(15):8397-406. PubMed ID: 24829337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the safety and protective efficacy of vaccination with glycoprotein-G-deficient infectious laryngotracheitis virus delivered via eye-drop, drinking water or aerosol.
    Devlin JM; Browning GF; Gilkerson JR; Fenton SP; Hartley CA
    Avian Pathol; 2008 Feb; 37(1):83-8. PubMed ID: 18202954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of a turkey herpesvirus vector laryngotracheitis vaccine for chickens.
    Esaki M; Noland L; Eddins T; Godoy A; Saeki S; Saitoh S; Yasuda A; Dorsey KM
    Avian Dis; 2013 Jun; 57(2):192-8. PubMed ID: 24689173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein G deficient infectious laryngotracheitis virus is a candidate attenuated vaccine.
    Devlin JM; Browning GF; Hartley CA; Gilkerson JR
    Vaccine; 2007 May; 25(18):3561-6. PubMed ID: 17316926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the protection elicited by direct and indirect exposure to live attenuated infectious laryngotracheitis virus vaccines against a recent challenge strain from the United States.
    Rodríguez-Avila A; Oldoni I; Riblet S; Garcia M
    Avian Pathol; 2008 Jun; 37(3):287-92. PubMed ID: 18568655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein-C-gene-deleted recombinant infectious laryngotracheitis virus expressing a genotype VII Newcastle disease virus fusion protein protects against virulent infectious laryngotracheitis virus and Newcastle disease virus.
    Wei X; Shao Y; Han Z; Sun J; Liu S
    Vet Microbiol; 2020 Nov; 250():108835. PubMed ID: 33011664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication of recombinant herpesvirus of turkey expressing genes of infectious laryngotracheitis virus in specific pathogen free and broiler chickens following in ovo and subcutaneous vaccination.
    Gimeno IM; Cortes AL; Guy JS; Turpin E; Williams C
    Avian Pathol; 2011 Aug; 40(4):395-403. PubMed ID: 21812719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Horizontal transmission dynamics of a glycoprotein G deficient candidate vaccine strain of infectious laryngotracheitis virus and the effect of vaccination on transmission of virulent virus.
    Devlin JM; Hartley CA; Gilkerson JR; Coppo MJ; Vaz P; Noormohammadi AH; Wells B; Rubite A; Dhand NK; Browning GF
    Vaccine; 2011 Aug; 29(34):5699-704. PubMed ID: 21689710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection induced by infectious laryngotracheitis virus vaccines alone and combined with Newcastle disease virus and/or infectious bronchitis virus vaccines.
    Vagnozzi A; García M; Riblet SM; Zavala G
    Avian Dis; 2010 Dec; 54(4):1210-9. PubMed ID: 21313841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Responses in the Eye-Associated Lymphoid Tissues of Chickens after Ocular Inoculation with Vaccine and Virulent Strains of the Respiratory Infectious Laryngotracheitis Virus (ILTV).
    Beltrán G; Hurley DJ; Gogal RM; Sharif S; Read LR; Williams SM; Jerry CF; Maekawa DA; García M
    Viruses; 2019 Jul; 11(7):. PubMed ID: 31295877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term protection against a virulent field isolate of infectious laryngotracheitis virus induced by inactivated, recombinant, and modified live virus vaccines in commercial layers.
    Palomino-Tapia VA; Zavala G; Cheng S; García M
    Avian Pathol; 2019 Jun; 48(3):209-220. PubMed ID: 30640536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses to infectious laryngotracheitis virus.
    Coppo MJ; Hartley CA; Devlin JM
    Dev Comp Immunol; 2013 Nov; 41(3):454-62. PubMed ID: 23567343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.